Delving into the Latest Updates on ST-294 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

TCRV glycoprotein

Mechanism

TCRV glycoprotein inhibitors(TCRV glycoprotein inhibitors)

Therapeutic Areas

Infectious Diseases

Active Indication

Virus Diseases

Inactive Indication-

Originator Organization

SIGA Technologies, Inc.

Active Organization

SIGA Technologies, Inc.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Author: Zhang, Yuanming ; Kickner, Shirley S ; Shurtleff, Amy C ; Amanda Lund, S ; Hruby, Dennis E ; Warren, Travis K ; Bleam, Maureen ; Kirkwood-Watts, Dana L ; Laquerre, Sylvie ; Bolken, Tove C ; Sperzel, Lindsey E ; Deng, Yijun ; King, David S ; Guttieri, Mary C ; Pevear, Daniel C ; Bailey, Thomas R ; Jones, Kevin F

Category A arenaviruses as defined by the National Institute of Allergy and Infectious Diseases (NIAID) are human pathogens that could be weaponized by bioterrorists. Many of these deadly viruses require biosafety level-4 (BSL-4) containment for all laboratory work, which limits traditional laboratory high-throughput screening (HTS) for identification of small molecule inhibitors. For those reasons, a related BSL-2 New World arenavirus, Tacaribe virus, 67-78% identical to Junín virus at the amino acid level, was used in a HTS campaign where approximately 400,000 small molecule compounds were screened in a Tacaribe virus-induced cytopathic effect (CPE) assay. Compounds identified in this screen showed antiviral activity and specificity against not only Tacaribe virus, but also the Category A New World arenaviruses (Junín, Machupo, and Guanarito). Drug resistant variants were isolated, suggesting that these compounds act through inhibition of a viral protein, the viral glycoprotein (GP2), and not through cellular toxicity mechanisms. A lead compound, ST-294, has been chosen for drug development. This potent and selective compound, with good bioavailability, demonstrated protective anti-viral efficacy in a Tacaribe mouse challenge model. This series of compounds represent a new class of inhibitors that may warrant further development for potential inclusion in a strategic stockpile.

100 Deals associated with ST-294

Login to view more data